MarketInOut Stock Screener Log In | Sign Up
 

Taysha Gene Therapies Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/22/2026 16:00
Taysha Gene Therapies Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,635.68 mln
Float321 mln
Earnings Date11/10/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-3.36
Reliable

Relative Strength

19 / 100
Significantly lagging

Debt / Equity

0.15
Very low leverage

Pre-Tax Margin

-2,728%
Severely loss-making

ROE

-56.94
Deeply negative

Business Description

Taysha Gene Therapies is a Dallas-based biotech company working to develop gene therapies for rare and serious brain and nervous system disorders caused by single gene defects. Founded in 2019, the company has a pipeline of treatments targeting conditions such as Rett syndrome, giant axonal neuropathy, and fragile X syndrome, among others. Taysha works in partnership with the University of Texas Southwestern Medical Center to advance its research.

Key Fundamentals

EPS-0.41
ROE-56.94
RPS0.01
ROIC-598
ROA-42.41
Interest Cover-3,647
EBITDA, mln-148
EV / EBITDA-9.98
EV / EBIT-9.90
Revenue, mln5.49
EV / Revenue270

Quote Details

Last 5.16
Change 0.12 (2.38%)
Open 5.11
Volume 2,304,171
Turnover 11,889,522
Average Volume 2,432,901

Financial Ratios

Pre-Tax Profit Margin-2,728
Leverage Ratio1.21
Current Ratio17.76
Price / Book4.85
Price / Tangible Book4.85
Debt / Equity0.15
Price / Sales385

Financial Strength

Altman Z-Score11.25
Piotroski F-Score 4 / 9
Beneish M-Score-3.36
Short Ratio18.16
Short % of Float14.59

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 1.98% 63 / 100   
1 Month -15.27% 12 / 100   
2 Months -13.57% 22 / 100   
6 Months 13.66% 67 / 100   
1 Year 82.33% 94 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us